Wolverine stack side effects and risks
An unapproved recovery blend with no controlled human trial of the premixed product.
Also called: Wolverine blend, BPC/TB blend.
Community blends · Unapproved BPC-157 and TB-500 mixture; ratios and ingredient identities vary.
Reported side effects
- Injection-site pain, redness or swelling: No reliable blend event rate; reports lack a denominator., moderate. Pause for persistent reactions; spreading heat or redness needs prompt assessment. (source)
- Serious allergic or immune reaction: FDA flags immune reaction risk; blend incidence is unknown., serious. Breathing trouble, throat swelling or collapse needs emergency care. (source)
- Infection from a contaminated injection: Product related risk; no measured blend rate., serious. Seek urgent care for fever with spreading redness or severe injection-site pain. (source)
- Darkening of skin and gums: FDA described one BPC/TB500 user with recurrence on re exposure; dose and causality uncertain., moderate. Stop further exposure and seek assessment for new widespread pigment changes. (source)
Stop and get help if
- Trouble breathing, throat swelling, collapse or fainting after an injection: Stop and call emergency services now.
- Hot, painful, spreading redness or swelling at an injection site: Stop injections and seek urgent same-day care; fever, confusion or fast breathing needs emergency care.
Who should avoid it
- pregnant: Precaution: no blend pregnancy safety data; pregnancy was excluded from the knee report.
- breastfeeding: Precaution: milk transfer and infant effects have not been studied for the blend.
- tryingToConceive: Precaution: reproductive safety and a safe washout period are unknown.
- under18: Precaution: no pediatric blend safety or dosing studies found.
- activeCancer: Precaution: ingredients promote blood-vessel growth in lab studies; effects on human tumors are unknown.
- cancerHistory: Review prior cancer with the treating clinician; long-term tumor effects have not been measured.
- kidneyDisease: Blend clearance and dose changes in kidney disease are unknown.
- liverDisease: Blend clearance and dose changes in liver disease are unknown.
- bleedingDisorder: Precaution for needle-related bruising and bleeding, especially with muscle injection.
- surgeryPlanned: Tell the surgical team about all ingredients; no safe perioperative stopping interval is established.
- testedAthlete: BPC-157 and TB-500 are prohibited at all times under the 2026 WADA list.
- other: Avoid re-exposure after a serious reaction; peptide impurities can trigger immune reactions.
Interactions
- Duplicate peptide products: Amounts add across vials and blends. No combination study establishes a safe total exposure.
- Oral anticoagulants: Muscle injections can increase bleeding or bruising. This is a needle-related risk; a chemical interaction with the blend is untested.
Product quality risks
- Label names may hide different TB4 molecules; fragment and full-length products are not interchangeable.
- FDA-reviewed ingredient COAs lacked some content, aggregate or endotoxin controls. HPLC purity alone cannot establish injection safety.
- Unauthorized injections may have wrong amounts, undeclared ingredients, microbes or endotoxins; blend defect rates are unknown.
Related to Wolverine stack (BPC-157 + TB-500)
- KLOW blend: GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
- GLOW blend (GHK-Cu + BPC-157 + TB-500): An unapproved skin-and-recovery blend with no human combination study found.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting, FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.